1. A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo. (April 2016) Authors: Pulles, A.E.; van Vulpen, L.F.; Schutgens, R.E.; van Meegeren, M.E.; Coeleveld, K.; Steen-Louws, C.; Hack, C.E.; Popov-Celeketic, J.; van Laar, J.M.; Mastbergen, S.C.; Lafeber, F.P. Journal: Osteoarthritis and cartilage Issue: Volume 24(2016)Supplement 1 Page Start: S505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0225 Proteomics for Prediction of Response in RA Using Both Classic and New Proposed Response Criteria. (10th June 2014) Authors: Cuppen, B.V.; de Jager, W.; Marijnissen, A.C.; Tekstra, J.; van der Veen, M.J.; Bijlsma, J.W.; van Laar, J.M.; Lafeber, F.P. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 878 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0239 Personalized Biological Treatment for Rheumatoid Arthritis: A Systematic Review with a Focus on Clinical Applicability. (9th June 2015) Authors: Cuppen, B.V.; Welsing, P.M.; Sprengers, J.J.; Bijlsma, J.W.; Marijnissen, A.C.; van Laar, J.M.; Lafeber, F.P.; Nair, S.C. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 971 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0275 The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients. (12th June 2018) Authors: Roodenrijs, N.M.T.; de Hair, M.J.H.; Wheater, G.; Elshahaly, M.; Tekstra, J.; Teng, Y.K.O.; Hwang, C.C.; Liu, X.; Sasso, E.H.; van Laar, J.M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Biochemical markers of joint tissue damage increase shortly after a joint bleed; an explorative human and canine in vivo study. Issue 1 (January 2015) Authors: van Vulpen, L.F.D.; van Meegeren, M.E.R.; Roosendaal, G.; Jansen, N.W.D.; van Laar, J.M.; Schutgens, R.E.G.; Mastbergen, S.C.; Lafeber, F.P.J.G. Journal: Osteoarthritis and cartilage Issue: Volume 23:Issue 1(2015) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0024 Contribution of the Individual Components of the Disease Activity Score (DAS28) to the Total DAS28 Score among Responders and Non-Responders to Biological Therapy for Rheumatoid Arthritis. (10th June 2014) Authors: Jurgens, M.S.; Overman, C.L.; Jacobs, J.W.; Geenen, R.; Cuppen, B.V.; Marijnissen, A.C.; Bijlsma, J.W.; Welsing, P.M.; Lafeber, F.P.; van Laar, J.M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FRI0040 Development and validation of clinical predictors for inadequate response to treat-to-target methotrexate therapy in newly diagnosed ra patients. (12th June 2018) Authors: Teitsma, X.M.; Jacobs, J.W.; Welsing, P.M.; de Jong, P.H.; Hazes, J.M.; Weel, A.E.; Pethö-Schramm, A.; Borm, M.E.; van Laar, J.M.; Lafeber, F.P.; Bijlsma, J.W. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0040 Protein Biomarkers Improves The Prediction of Clinical Response To Methotrexate Step-Up Strategy in Early RA Patients. (15th July 2016) Authors: Teitsma, X.M.; Jacobs, J.W.; Welsing, P.M.; Woodworth, T.G.; Pethö-Schramm, A.; Borm, M.E.; Bernasconi, C.; van Laar, J.M.; Bijlsma, J.W.; Lafeber, F.P. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0268 Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from The Open-Label Period of The Fasscinate Trial. (15th July 2016) Authors: Khanna, D.; Denton, C.P.; Jahreis, A.; van Laar, J.M.; Burke, L.; Spotswood, H.; Lin, C.J.; Pope, J.E.; Allanore, Y.; Müller-Ladner, U.; Siegel, J.; Furst, D.E. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Knee joint distraction compared to total knee arthroplasty for treatment of end stage osteoarthritis: simulating long-term outcomes and cost-effectiveness. (April 2016) Authors: van der Woude, J.-T.; Nair, S.C.; Custers, R.J.; van Laar, J.M.; Mastbergen, S.C.; Welsing, P.M.; Lafeber, F.P. Journal: Osteoarthritis and cartilage Issue: Volume 24(2016)Supplement 1 Page Start: S426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗